1. S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Busse, WW; Muñoz, X; Casale, TB; Paggiaro, P; Castro, M; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S49 Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the LIBERTY ASTHMA QUEST study. (12th November 2019) Authors: Paggiaro, P; Castro, M; Canonica, WG; Douglass, JA; Tohda, Y; Rice, MS; Deniz, Y; Rowe, P; Amin, N; Teper, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗